What is a clinical trial?
Clinical trials provide the latest in medical treatments for cancer before they are made available to the general public as standard treatment. Treatments are administered under carefully controlled conditions, which allow doctors and researchers to learn about their effectiveness, as well as possible side effects. Patients are carefully selected, to be sure the treatment is appropriate for their particular disease and current state of health. Participants will work with doctors and health care professionals at every stage of a clinical trial.
Some patients choose to participate in clinical trials in hopes of a better response to treatment or increase in survival by using newer drugs or therapies. Some patients feel that participation in clinical trials will help others - family, friends, or even strangers - as well as themselves. Many patients feel the close follow-up and re-testing schedules used to check results of the treatment on a clinical trial ensures a thorough schedule of care.
Participate in a clinical trial
Review the open clinical trials below. To determine if you are eligible, or for more information, contact Beth Davis at (707) 523-7316 or davismb1 (at) sutterhealth.org.
Basal Cell Carcinoma-Skin
- A Phase II double-blind study to evaluate the different in vismodegib regimens for patients with multiple (6 or more) basal cell carcinomas
- A Phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy
- A phase III randomized trial of adjuvant therapy comparing chemotherapy alone (six cycles of TC or four cycles of AC followed by four cycles of weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-normal invasive breast cancer
- Placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancer in patients with stage 0-III colon cancer
- A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
- A Phase III randomized trial of cisplatin and docetaxel with or without bevacizumab in patients with recurrent or metastatic head and neck cancer
- Randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of darbepoetin alfa every three weeks in stage IV lung cancer anemic patients
- A Phase III randomized study of adjuvant ipilimumab anti-CTLA4 therapy versus high-dose interferon α-2b for resected high-risk melanoma
- A Phase III double-blind, placebo-controlled study of vemurafeib versus. vemurafenib + GDC-0973 in previously untreated BRAF+ patients with unresectable locally advanced or metastatic melanoma
- Double blind study of oral MLN9708 (Velcade) + Revlimid/ dexamethasone versus Revlimid/ dexamethasone + placebo in newly diagnosed multiple myeloma
- Randomized open-label study of pomalidomide, Velcade + low-dose dexamethasone versus Velcade + low-dose dexamethasone
- A Phase II randomized study of azacitidine with Revlimid versus azacitidine alone versus azacitidine with vorinostat for CMML and MDS
- A Phase II trial of AZD6244 hydrogen sulfate & MK-2206 vs FOLFOX in patients with metastatic pancreatic cancer after prior chemotherapy
- A Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage Ib - IIIa non-small cell lung cancer (NSCLC)
- A randomized, Phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC)
- A randomized Phase III study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy versus immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer
- EVErolimus for Renal Cancer. A Phase III Study. (Intermediate, High Risk or Very High Risk)
- A Phase II randomized study of ARQ 197 and ARQ 197 in combination with erlotinib in locally advanced, unresectable, or metastatic papillary renal cell cancer
- A Phase III, randomized, double-blinded study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma